Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Are brain implants ready to become medical products?

    As of October 2026, China has approved an implanted brain-computer interface for market use, while in the US the leading long-term implants remain in early feasibility studies and the cleared next-generation device, a surface array, is limited to 30 days.[1][2][3][4] Supporters point to safety data and rapid gains in performance; sceptics point to tiny trials, durability questions and the lack of post-trial support and insurance pathways.[5][6][7][8]

    Editor reviewedStrict sourcingUpdated Neuroscience and brain-computer interfacesHealth and medicineLife sciences
    Show:

    The question

    Brain-computer interfaces have worked in research for two decades, from cursor control in 2006 to conversational speech in 2024.[9][6] The question now is whether implanted BCIs are ready to move from feasibility studies to approved medical products that people can get outside a trial.

    What we know

    Regulatory status. As of December 2024, FDA had not granted marketing authorization for any implantable BCI.[10] In April 2025 FDA cleared Precision Neuroscience’s Layer 7 surface array, but only for implantation of up to 30 days.[2] In March 2026 China’s NMPA approved Neuracle’s implantable hand-motor BCI for market use.[1] In July 2026 the PRIMA retinal implant, a vision-restoring BCI, received European CE marking.[11] The same month it received two FDA Humanitarian Use Device designations, and as of October 2026 it is pending FDA approval.[12][13]

    Trial sizes. Neuralink reported 21 participants worldwide in January 2026.[14] Synchron had implanted 10 people by November 2025.[15] Paradromics’ Connect-One study initially enrols two participants.[4] Neuralink’s VOICE speech study plans about six.[16]

    Safety signals. Synchron’s six-patient COMMAND study met its one-year primary safety endpoint.[5] Neuralink reports zero serious device-related adverse events.[17] The PRIMA retinal trial recorded 26 serious adverse events in 19 of 38 participants, most soon after surgery.[18]

    Durability. Neuralink’s first participant lost effective electrodes when threads retracted.[19] Paradromics’ four-year stability data come from two sheep.[20]

    Access. Some trial participants have had BCIs removed when post-trial funding or support ended, and experts told GAO that engaging Medicare on coverage is difficult.[7][8]

    Money. Neuralink raised $650 million in June 2025, Synchron $200 million in November 2025 and Precision $250 million in 2026, each citing clinical expansion or commercialization.[21][22][23]

    How to read the evidence

    The safety record is encouraging but statistically weak. A one-year endpoint met by six patients, or a company-reported clean record across a few dozen, cannot rule out uncommon complications; that is the job of pivotal trials, which FDA guidance anticipates for implanted BCIs.[5][17][24]

    Performance is less of a bottleneck than it was. Peer-reviewed speech systems already reach accuracy that supports daily conversation for one participant, so the open questions are reproducibility across many users and durability over years.[6][25]

    The first approvals outside the US differ from the devices in US trials. China’s approved system restores partial hand function, and PRIMA restores vision through the eye rather than recording from the brain, so neither settles whether high-channel cortical implants for communication are ready.[1][18]

    Access may lag approval. GAO’s findings on device removal after trials and on Medicare coverage suggest that even an approved implant would face reimbursement and long-term support questions.[7][8]

    What could happen next

    A US pivotal study of an implanted BCI looks likely to be announced within the next year, given Synchron’s stated plan to accelerate pivotal trials and its November 2025 funding; we would put this at moderate-to-high likelihood, but timing depends on FDA and was not confirmed by primary sources as of October 2026.[22]

    First US marketing authorization for a long-term implanted communication BCI is unlikely before 2028, because pivotal trials typically take years and none had demonstrably begun by October 2026. This is our estimate, with low confidence.[24][10]

    More approvals in China seem likely, given that a July 2026 analysis counted five NMPA-approved BCI-related products and 134 registered trials.[26]

    Competing views

    Ready for pivotal trials and first approvals

    Small studies show no serious device-related harms over a year, performance now supports real conversation, and well-funded companies are moving to pivotal trials.[5][6][22][17]

    Evidence is still too thin

    Trials involve a handful of people per device, headline results come from single participants, long-term human durability is unproven, and some users have lost devices after trials ended.[15][19][20][7]

    Approval is happening abroad first

    China's regulator approved an invasive BCI in March 2026 and a retinal BCI won European CE marking in July 2026, while FDA had authorized no long-term implantable BCI as of GAO's latest review.[1][11][10]

    Questions readers ask

    Has any country approved an implanted brain-computer interface?

    Yes. In March 2026 China's National Medical Products Administration approved an implantable BCI hand-motor system from Neuracle, described as the world's first invasive BCI medical device approved for market use.[1]

    Is any brain implant approved in the US?

    As of GAO's December 2024 review, FDA had not authorized any implantable BCI for marketing. Precision Neuroscience's Layer 7 surface array was cleared in April 2025, but only for implantation of up to 30 days.[10][2]

    How many people have received the leading US implants?

    Neuralink reported 21 trial participants in January 2026, Synchron 10 by November 2025, and Paradromics announced its first implant in June 2026.[14][15][27]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      In March 2026 China's National Medical Products Administration approved an implantable BCI hand-motor system from Neuracle Medical Technology, described as the world's first invasive BCI medical device approved for market use. confirmedas of 2026-03-14

    2. [2]

      In April 2025 Precision Neuroscience received FDA 510(k) clearance for its Layer 7 Cortical Interface, authorizing commercial use with implantation of up to 30 days. confirmedas of 2025-04-17

    3. [4]

      In November 2025 FDA granted Paradromics an Investigational Device Exemption for the Connect-One early feasibility study of its Connexus BCI to restore speech and computer control, initially enrolling two participants. confirmedas of 2025-11-20

    4. [5]

      Synchron's US COMMAND early feasibility study enrolled six patients with severe paralysis, and all met the primary endpoint of no device-related serious adverse events causing death or permanent increased disability over one year. confirmedas of 2024-10-03

    5. [6]

      The UC Davis neuroprosthesis reached 99.6 percent accuracy on a 50-word vocabulary on its first day of use and sustained 97.5 percent accuracy over 8.4 months, with the participant conversing at about 32 words per minute for more than 248 hours. confirmedas of 2024-08-15

    6. [7]

      Experts told GAO that some clinical trial participants have had a BCI removed because there were no funds or medical support after the trial. confirmedas of 2024-12-17

    7. [8]

      Experts told GAO it can be challenging to interact with the Centers for Medicare and Medicaid Services about BCIs, whose coverage decisions private insurers often use as a guide. confirmedas of 2024-12-17

    8. [9]

      In a 2006 Nature study, a man with tetraplegia used a 96-microelectrode array implanted in his primary motor cortex to move a computer cursor, open simulated e-mail and operate a prosthetic hand. confirmedas of 2006-07-13

    9. [10]

      As of December 2024, FDA had not granted marketing authorization for any implantable device for BCI use. confirmedas of 2024-12-17

    10. [11]

      In July 2026 Science Corporation's PRIMA retinal implant received CE marking, allowing sale across 30 European countries, and the company announced its European commercial launch. confirmedas of 2026-07-22

    11. [12]

      In July 2026 Science Corporation said PRIMA had received two FDA Humanitarian Use Device designations, for blindness from advanced geographic atrophy and for vision loss from Stargardt disease; the device still needs FDA approval through a Humanitarian Device Exemption. confirmedas of 2026-07-22

    12. [13]

      As of October 2026 Science Corporation describes PRIMA as commercially available in Europe and the United Kingdom and pending FDA approval in the United States. confirmedas of 2026-10-05

    13. [15]

      As of November 2025 Synchron's Stentrode had been implanted in 10 patients with paralysis across trials in the US and Australia. confirmedas of 2025-11-06

    14. [18]

      In a 38-participant trial of the PRIMA subretinal implant for geographic atrophy, 26 of 32 people assessed at 12 months (81 percent) had a clinically meaningful improvement in visual acuity; 26 serious adverse events occurred in 19 participants, 21 of them within two months after surgery. confirmedas of 2025-10-20

    15. [20]

      In October 2026 Paradromics reported four years of stable neural recording in two sheep implanted with cortical modules representative of its electrode technology, with no electrode-array migration observed. confirmedas of 2026-10-08

    16. [22]

      Synchron raised a $200 million Series D in November 2025, bringing its total funding to $345 million, to prepare pivotal trials and develop a next-generation high-channel interface delivered by catheter. confirmedas of 2025-11-06

    17. [23]

      Precision Neuroscience closed a $250 million Series D in 2026, bringing its total funding to $430 million, to expand clinical programs, pursue further FDA review of Layer 7 and build commercial infrastructure. confirmedas of 2026-10-10

    18. [24]

      FDA issued final guidance in May 2021 on non-clinical testing and clinical study design for implanted BCI devices for patients with paralysis or amputation, covering both feasibility and pivotal studies. confirmedas of 2021-05-20

    19. [25]

      In the UC Davis speech neuroprosthesis study, a 45-year-old man with ALS received four microelectrode arrays with 256 electrodes in his left ventral precentral gyrus. confirmedas of 2024-08-15

    20. [26]

      A July 2026 preprint counted five BCI-related products approved by China's NMPA as of June 2026 and 134 registered BCI trials, 79.1 percent of them using non-invasive systems and 65 percent targeting stroke rehabilitation. confirmedas of 2026-07-08

    21. [27]

      On June 17, 2026 Paradromics and University of Michigan Health announced the first Connexus implantation in the Connect-One study, in a woman with motor neuron disease who has difficulty speaking. confirmedas of 2026-06-17

    Revision history (2)
    1. Page created.
    2. Refresh: added PRIMA's FDA Humanitarian Use Device designations.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Are brain implants ready to become medical products?." ContentLora, updated Oct 10, 2026. https://contentlora.com/analysis/bci-readiness-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents